The purpose of the research study is to see if stronger magnetic resonance imaging (MRI) machines can provide more information about bladder cancer before and during surgery.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT00938145.
PRIMARY OBJECTIVES:
I. To evaluate whether 3 Tesla MRI can accurately determine the primary tumor (T) stage and pelvic lymph nodes (N) stage for localized bladder cancer. The ability of 3 Tesla MRI to accurately assign stage will be compared to histopathology staging.
SECONDARY OBJECTIVES:
I. To determine whether 3 Tesla MRI can determine if the primary bladder tumor is responding to neoadjuvant chemotherapy at the mid-point of the planned treatment (after 2 cycles).
II. To assess whether an ultra-high-field MRI (> 3 Tesla) tissue scan can more accurately determine clinical stage of a primary bladder tumor and regional lymph nodes.
OUTLINE:
All patients undergo 3-Tesla MRI scans 2-4 weeks before surgery. Patients receiving neoadjuvant chemotherapy also undergo 3-Tesla MRI scans before the start of chemotherapy and after 2 courses of chemotherapy. Specimens collected during surgery are then assessed via ultra-high-field MRI.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationOhio State University Comprehensive Cancer Center
Principal InvestigatorMichael Vinzenz Knopp